Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jel… Read more
Jia Jie Biomedical Co Ltd (4109) - Total Liabilities
Latest total liabilities as of September 2025: NT$159.28 Million TWD
Based on the latest financial reports, Jia Jie Biomedical Co Ltd (4109) has total liabilities worth NT$159.28 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jia Jie Biomedical Co Ltd - Total Liabilities Trend (2015–2024)
This chart illustrates how Jia Jie Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jia Jie Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jia Jie Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Denarius Silver Corp
OTCQB:DNRSF
|
USA | $61.45 Million |
|
Tesmec S.p.A.
PINK:TSMCF
|
USA | $354.11 Million |
|
ImmuCell Corporation
NASDAQ:ICCC
|
USA | $15.93 Million |
|
Woowon Development Co. Ltd
KQ:046940
|
Korea | ₩118.27 Billion |
|
MLG OZ Ltd
AU:MLG
|
Australia | AU$174.09 Million |
|
Dekpol SA
WAR:DEK
|
Poland | zł1.19 Billion |
|
Parlem Telecom Companyia de Telecomunicacions S.A.
MC:PAR
|
Spain | €49.54 Million |
|
Khonburi Sugar Public Company Limited
BK:KBS
|
Thailand | ฿7.45 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down Jia Jie Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jia Jie Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jia Jie Biomedical Co Ltd (2015–2024)
The table below shows the annual total liabilities of Jia Jie Biomedical Co Ltd from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$123.08 Million | -64.08% |
| 2023-12-31 | NT$342.69 Million | +328.38% |
| 2022-12-31 | NT$80.00 Million | -7.48% |
| 2021-12-31 | NT$86.47 Million | +6.17% |
| 2020-12-31 | NT$81.44 Million | -49.39% |
| 2019-12-31 | NT$160.92 Million | -60.21% |
| 2018-12-31 | NT$404.40 Million | -34.94% |
| 2017-12-31 | NT$621.58 Million | -9.25% |
| 2016-12-31 | NT$684.91 Million | +14.95% |
| 2015-12-31 | NT$595.84 Million | -- |